These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18276038)

  • 1. The effect of dendrimers on the pharmacodynamic and pharmacokinetic behaviors of non-covalently or covalently attached drugs.
    Cheng Y; Xu T
    Eur J Med Chem; 2008 Nov; 43(11):2291-7. PubMed ID: 18276038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex.
    Patri AK; Kukowska-Latallo JF; Baker JR
    Adv Drug Deliv Rev; 2005 Dec; 57(15):2203-14. PubMed ID: 16290254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendrimers in biomedical applications--reflections on the field.
    Svenson S; Tomalia DA
    Adv Drug Deliv Rev; 2005 Dec; 57(15):2106-29. PubMed ID: 16305813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendrimers as versatile platform in drug delivery applications.
    Svenson S
    Eur J Pharm Biopharm; 2009 Mar; 71(3):445-62. PubMed ID: 18976707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advances in the investigation of biological effect and surface modification of dendrimers as drug (gene) delivery systems].
    He ZH; Kong H; Xu HY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Aug; 28(4):590-5. PubMed ID: 16995320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recent advances in the study of dendrimers-based drug delivery systems].
    Zheng C; Qiao MX; Yan L; Hu HY; Chen DW
    Yao Xue Xue Bao; 2007 Sep; 42(9):924-9. PubMed ID: 18050732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface modified poly(amido)amine dendrimers as diverse nanomolecules for biomedical applications.
    Yellepeddi VK; Kumar A; Palakurthi S
    Expert Opin Drug Deliv; 2009 Aug; 6(8):835-50. PubMed ID: 19637972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendrimers: emerging polymers for drug-delivery systems.
    Nanjwade BK; Bechra HM; Derkar GK; Manvi FV; Nanjwade VK
    Eur J Pharm Sci; 2009 Oct; 38(3):185-96. PubMed ID: 19646528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties.
    Kaminskas LM; Boyd BJ; Porter CJ
    Nanomedicine (Lond); 2011 Aug; 6(6):1063-84. PubMed ID: 21955077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
    Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
    Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic and diagnostic applications of dendrimers for cancer treatment.
    Wolinsky JB; Grinstaff MW
    Adv Drug Deliv Rev; 2008 Jun; 60(9):1037-55. PubMed ID: 18448187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEGylated dendrimers with core functionality for biological applications.
    Guillaudeu SJ; Fox ME; Haidar YM; Dy EE; Szoka FC; Fréchet JM
    Bioconjug Chem; 2008 Feb; 19(2):461-9. PubMed ID: 18173227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats.
    Boyd BJ; Kaminskas LM; Karellas P; Krippner G; Lessene R; Porter CJ
    Mol Pharm; 2006; 3(5):614-27. PubMed ID: 17009860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supramolecular structures from dendrons and dendrimers.
    Al-Jamal KT; Ramaswamy C; Florence AT
    Adv Drug Deliv Rev; 2005 Dec; 57(15):2238-70. PubMed ID: 16310885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview.
    Mignani S; El Kazzouli S; Bousmina M; Majoral JP
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1316-30. PubMed ID: 23415951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendrimer biocompatibility and toxicity.
    Duncan R; Izzo L
    Adv Drug Deliv Rev; 2005 Dec; 57(15):2215-37. PubMed ID: 16297497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of dendrimers and drug-dendrimer conjugates for drug delivery.
    Najlah M; D'Emanuele A
    Curr Opin Drug Discov Devel; 2007 Nov; 10(6):756-67. PubMed ID: 17987527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development and applications of dendrimers in biomedicine].
    Huang F; Xu L; Xu H
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Feb; 22(1):197-201. PubMed ID: 15762149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting cancer cells with biotin-dendrimer conjugates.
    Yang W; Cheng Y; Xu T; Wang X; Wen LP
    Eur J Med Chem; 2009 Feb; 44(2):862-8. PubMed ID: 18550227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigations on surface modified dendrimers: enzymatic hydrolysis and uptake into MCF-7 breast cancer cells.
    Kapp T; Francke P; Gust R
    ChemMedChem; 2008 Apr; 3(4):635-41. PubMed ID: 18200649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.